Komori
Results8275FORVAL CORPORATIONTrading & Wholesale

Financial Results Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

For the interim period of the fiscal year ending March 2027, revenue was ¥35,436 million and operating income was ¥1,265 million, resulting in year-on-year increases in both revenue and operating income. The full-year earnings forecast and dividend forecast remain unchanged, with an annual dividend of ¥32 expected.

Worth reading
48Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
4.4
Year-on-year change in net sales (%)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales35,436¥ millionYear on year +4.4%Progress 46.0%
Operating profit1,265¥ millionYear on year +5.2%Progress 30.9%
Ordinary income1,463¥ millionYear on year +8.5%Progress 34.0%
Net income attributable to owners of the parent616¥ millionYear on year +2.4%Progress 28.0%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥23.60
Financial position at period-end
Total assets40,962¥ million
of which net assets 21,223 ¥ millionEquity ratio 45.7%vs. prior year-end +0.5pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-953,082
Investment-173,567
Financials-709,939
Net change-1,836,588

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥10,311,147 thousand
Segment revenueCorporate Doctor Group ¥17,680 million (YoY +2.9%), Business Solutions Group ¥17,756 million (YoY +6.0%)
Segment profitCorporate Doctor Group ¥737 million (YoY +74.3%), Business Solutions Group ¥524 million (YoY -32.3%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥77,000 million (YoY +7.7%)
Operating profit¥4,100 million (YoY +10.1%)
Ordinary income¥4,300 million (YoY +6.3%)
Net income¥2,200 million (YoY +48.9%)
Revision to Earnings ForecastNo change
Annual Dividend Forecast¥31 → ¥32(+3.2%)
Factors Behind Changes in Business Performance

In response to growing momentum behind digital transformation, the visualisation and hands-on management support business provided by corporate doctors remained solid, while revenue from servers and electricity services increased. Selling, general and administrative expenses rose due to higher personnel costs, information processing expenses, and travel and transportation expenses, while other expenses were kept under control.

Disclosure regarding the going concern assumption

Not applicable.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew — companies / Excluded — companies / Company name Not disclosed
Impairment loss¥104 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥3,260 thousand, Gain on sale of non-current assets ¥441 thousand, Insurance proceeds received ¥9,040 thousand / Extraordinary loss Loss on disposal and sale of fixed assets ¥4,757 thousand, Impairment Losses ¥104 thousand, Directors' Retirement Benefits ¥6,891 thousand, Other ¥702 thousand
Depreciation and amortization¥906,270 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingHeld Yes / Subject person For analysts, institutional investors and individual investors
Issued Shares at Period-End27,732,622
Treasury Shares at Period-End1,619,232
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥35,436 million (YoY +4.4%)
Operating profit¥1,265 million (YoY +5.2%)
Ordinary income¥1,463 million (YoY +8.5%)
Profit attributable to owners of the parent¥616 million (YoY +2.4%)
Net income per share¥23.60
Equity ratioEnd of the current fiscal period 45.7% / End of previous period 45.2%
Total assets¥40,962 million
Net assets¥21,223 million
Cash flows from operating activities¥-953,082 thousand
Cash flows from investing activities¥-173,567 thousand
Cash flows from financing activities¥-709,939 thousand
Cash and cash equivalents at end of period¥10,311,147 thousand
Full-year earnings forecastNet Sales ¥77,000 million (YoY +7.7%) / Operating profit ¥4,100 million (YoY +10.1%) / Ordinary income ¥4,300 million (YoY +6.3%) / Net income ¥2,200 million (YoY +48.9%)
Revision to Earnings ForecastNo change
Annual Dividend Forecast¥31 → ¥32(+3.2%)
Segment revenueCorporate Doctor Group ¥17,680 million (YoY +2.9%), Business Solutions Group ¥17,756 million (YoY +6.0%)
Segment profitCorporate Doctor Group ¥737 million (YoY +74.3%), Business Solutions Group ¥524 million (YoY -32.3%)
Depreciation and amortization¥906,270 thousand
Impairment loss¥104 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥3,260 thousand, Gain on sale of non-current assets ¥441 thousand, Insurance proceeds received ¥9,040 thousand / Extraordinary loss Loss on disposal and sale of fixed assets ¥4,757 thousand, Impairment Losses ¥104 thousand, Directors' Retirement Benefits ¥6,891 thousand, Other ¥702 thousand
Disclosure regarding the going concern assumptionNot applicable.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew — companies / Excluded — companies / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingHeld Yes / Subject person For analysts, institutional investors and individual investors
Issued Shares at Period-End27,732,622
Treasury Shares at Period-End1,619,232
Factors Behind Changes in Business PerformanceIn response to growing momentum behind digital transformation, the visualisation and hands-on management support business provided by corporate doctors remained solid, while revenue from servers and electricity services increased. Selling, general and administrative expenses rose due to higher personnel costs, information processing expenses, and travel and transportation expenses, while other expenses were kept under control.
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In response to growing momentum behind digital transformation, the visualisation and hands-on management support business provided by corporate doctors remained solid, while revenue from servers and electricity services increased. Personnel costs required to strengthen staffing for the growth strategy, information processing expenses, and travel and transportation expenses also increased, while other expenses were kept under control.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | FORVAL CORPORATION (8275) timely disclosure | Komori